• Giuseppe TridenteEmail author


The amount of biological molecules already in use in human therapy and the consistency of the promised new entries demand attention to clinicians, oncologists, rheumatologists, immunologists, allergologists, to health care professionals, and to public health surveillance. It is reasonable to assume that, together with the new entries and their massive therapeutic expansion, an increasing number of known adverse events and new reactions are to be expected, and will need to be observed, possibly prevented, and controlled.


Adverse Drug Event Biological Response Modifier Public Health Surveillance Autoinflammatory Disease Adverse Event Follow Immunization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Edwards IR, Biriell C (1994) Harmonization in pharmacovigilance. Drug Saf 10:93–102PubMedCrossRefGoogle Scholar
  2. 2.
    Bankowski Z, Bruppacher R, Crusius I et al (2000) Reporting adverse drug reactions. Definitions of terms and criteria for their use. CIOMS, Geneva (ISBN 92 9036 071 2)Google Scholar
  3. 3.
    Common Terminology Criteria for Adverse Events (CTCAE) v. 4.03 NCI June 2010, (
  4. 4.
    Note for guidance on clinical safety data management: definitions and standards for expedite reporting (CPMP/ICH/377/95) EMEA ICH topic E2A Step 5. 1995/2006Google Scholar
  5. 5.
    WHO draft guidelines for adverse event reporting and learning systems. From information to action (2005) WHO, (
  6. 6.
    Wallenbeck I (2010) Safety monitoring and reporting for clinical trials in Europe, ( document_library/Presentation/2010/06/WC00093378.pdf)
  7. 7.
    NCI guidelines for investigators: adverse event reporting requirements for DCDT (CTEP and CIP) and DCP INDs and IDEs. March 2011 ( Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations